Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: decitabine/cedazuridine Clear all
Recruiting Phase 1Phase 2 Interventional

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT05010122
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine, Gilteritinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

NCT04953910
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Terminated Phase 2 Interventional Results available

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

NCT04878432
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
MBG453, Azacitidine, Decitabine, INQOVI (oral decitabine)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT06191978
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ASTX727, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

NCT04340843
View directory record Official record
Conditions
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

NCT04746235
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

NCT05010772
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine, Enasidenib, Gilteritinib, Ivosidenib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 2 Interventional

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

NCT07710534
View directory record Official record
Conditions
Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
Interventions
Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN)
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

NCT03922555
View directory record Official record
Conditions
Neurological Cancer
Interventions
ASTX727
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Not yet recruiting Phase 2 Interventional

Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML

NCT07867626
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML)
Interventions
Venetoclax, Decitabine/Cedaruridine, decitabine/cedazuridine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT05272384
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Duarte, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

NCT03613532
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
Interventions
Venetoclax, Fludarabine, Busulfan, Azacitidine, Decitabine/cedazuridine
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Active, not recruiting Phase 1 Interventional

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

NCT03875287
View directory record Official record
Conditions
Solid Tumor
Interventions
Decitabine, Cedazuridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

NCT07012044
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

BMS-986253 in Myelodysplastic Syndromes

NCT05148234
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253, Bone Marrow Biopsy, Bone Marrow Aspiration, ECG
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

NCT04742634
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
DEC-C, MyeloSeq-HD
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

NCT03306264
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
ASTX727, Dacogen
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
39
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 14, 2026, 10:52 AM EDT
Active, not recruiting Phase 2 Interventional

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax, INQOVI (oral decitabine)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

NCT05835011
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Decitabine/Cedazuridine, Magrolimab
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
New Haven, Connecticut • Plantation, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 14, 2026, 10:52 AM EDT
Suspended Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Costa Mesa, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

NCT05360160
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
SNDX-5613, Venetoclax, ASTX727
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

NCT02103478
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS
Interventions
ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 14, 2026, 10:52 AM EDT
Active, not recruiting Phase 2 Interventional

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

NCT05007873
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Dasatinib, Decitabine and Cedazuridine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 10:52 AM EDT
Recruiting Early Phase 1 Interventional

Early Intervention in High Risk CCUS

NCT06802146
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Cytopenia
Interventions
Inqovi
Drug
Lead sponsor
Lachelle D. Weeks, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 14, 2026, 10:52 AM EDT